Effect of Diclofenac Etalhyaluronate (SI-613) on the Production of High Molecular Weight Sodium Hyaluronate in Human Synoviocytes

Overview

Journal BMC Musculoskelet Disord

Publisher Biomed Central

Specialties Orthopedics
Physiology

Date 2019 May 12

PMID 31077160

Citations 11

Authors

Tomochika Kisukeda

Junichi Onaya

Keiji Yoshioka

Affiliations

Soon will be listed here.

Abstract

Background: We have reported that a single intra-articular injection of diclofenac etalhyaluronate (SI-613) exerted a potent and long-lasting analgesic effect in experimental arthritis models. In the present study, we investigated the effect of SI-613 on the production of high molecular weight hyaluronic acid (HMW-HA) in synoviocytes from osteoarthritis (OA) patients and compared its efficacy with that of hyaluronic acid (HA).

Methods: We compared the effect of SI-613, HA, and diclofenac sodium (DF-Na) on high molecular weight HA production by human synoviocytes.

Results: SI-613 and exogenous HA induced the production of high molecular weight HA in synoviocytes from OA patients, whereas DF-Na had no effect. The molecular weight of newly produced HA was about 1000 kDa in the HA-treated synoviocytes and much higher than 2400 kDa in the SI-613-treated cells. The effect of the mixture of HA and DF-Na was similar to that of HA alone in that the molecular weight of newly produced HA was around 1000 kDa. SI-613 significantly suppressed hyaluronidase 2 (HYAL2) mRNA expression and significantly enhanced hyaluronan synthase 2 (HAS2) mRNA expression. HA had no effect on the expression levels of HYAL and HAS.

Conclusion: The present results clearly demonstrate that SI-613 induces the production of high molecular weight HA in synoviocytes from OA patients, suggesting the long-lasting analgesic and disease modifying effect of SI-613 for OA. Taken together with the anti-inflammatory and analgesic effects we recently reported for the intra-articular administration of SI-613 to experimental animal models, SI-613 holds great promise for the treatment of knee osteoarthritis.

Citing Articles

Lubrication for Osteoarthritis: From Single-Function to Multifunctional Lubricants.

Chen W, Ye Q, Zhang M, Xie R, Xu C Int J Mol Sci. 2025; 26(5).

PMID: 40076486 PMC: 11900089. DOI: 10.3390/ijms26051856.

Effects of Diclofenac Etalhyaluronate (SI-613/ONO-5704) on Cartilage Degeneration in Arthritic Rats and Inflammatory Cytokine-Stimulated Human Chondrocytes.

Takada S, Nodera R, Yoshioka K Cartilage. 2024; :19476035231224050.

PMID: 38317317 PMC: 11569655. DOI: 10.1177/19476035231224050.

Polysaccharides-Naturally Occurring Immune Modulators.

Murphy E, Fehrenbach G, Abidin I, Buckley C, Montgomery T, Pogue R Polymers (Basel). 2023; 15(10).

PMID: 37242947 PMC: 10222865. DOI: 10.3390/polym15102373.

Composing On-Program Triggers and On-Demand Stimuli into Biosensor Drug Carriers in Drug Delivery Systems for Programmable Arthritis Therapy.

Lim Y, Zaidi A, Miskon A Pharmaceuticals (Basel). 2022; 15(11).

PMID: 36355502 PMC: 9698912. DOI: 10.3390/ph15111330.

Analgesic effects and arthritic changes following intra-articular injection of diclofenac etalhyaluronate in a rat knee osteoarthritis model.

Arai T, Suzuki-Narita M, Takeuchi J, Tajiri I, Inage K, Kawarai Y BMC Musculoskelet Disord. 2022; 23(1):960.

PMID: 36344944 PMC: 9641934. DOI: 10.1186/s12891-022-05937-y.

References

Brinck J, Heldin P . Expression of recombinant hyaluronan synthase (HAS) isoforms in CHO cells reduces cell migration and cell surface CD44. Exp Cell Res. 1999; 252(2):342-51. DOI: 10.1006/excr.1999.4645. View

. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 2000; 43(9):1905-15. DOI: 10.1002/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P. View

Itano N, Kimata K . Mammalian hyaluronan synthases. IUBMB Life. 2003; 54(4):195-9. DOI: 10.1080/15216540214929. View

OGSTON A, STANIER J . The physiological function of hyaluronic acid in synovial fluid; viscous, elastic and lubricant properties. J Physiol. 1953; 119(2-3):244-52. PMC: 1392794. DOI: 10.1113/jphysiol.1953.sp004842. View

Buckwalter J, Saltzman C, Brown T . The impact of osteoarthritis: implications for research. Clin Orthop Relat Res. 2004; (427 Suppl):S6-15. DOI: 10.1097/01.blo.0000143938.30681.9d. View

Stern R . Hyaluronan metabolism: a major paradox in cancer biology. Pathol Biol (Paris). 2005; 53(7):372-82. DOI: 10.1016/j.patbio.2004.12.021. View

Santangelo K, Johnson A, Ruppert A, Bertone A . Effects of hyaluronan treatment on lipopolysaccharide-challenged fibroblast-like synovial cells. Arthritis Res Ther. 2007; 9(1):R1. PMC: 1860057. DOI: 10.1186/ar2104. View

Zhang W, Moskowitz R, Nuki G, Abramson S, Altman R, Arden N . OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008; 16(2):137-62. DOI: 10.1016/j.joca.2007.12.013. View

David-Raoudi M, Deschrevel B, Leclercq S, Galera P, Boumediene K, Pujol J . Chondroitin sulfate increases hyaluronan production by human synoviocytes through differential regulation of hyaluronan synthases: Role of p38 and Akt. Arthritis Rheum. 2009; 60(3):760-70. DOI: 10.1002/art.24302. View

10.

Zhang W, Nuki G, Moskowitz R, Abramson S, Altman R, Arden N . OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010; 18(4):476-99. DOI: 10.1016/j.joca.2010.01.013. View

11.

Altman R, Dasa V, Takeuchi J . Review of the Mechanism of Action for Supartz FX in Knee Osteoarthritis. Cartilage. 2017; 9(1):11-20. PMC: 5724672. DOI: 10.1177/1947603516684588. View

12.

Yoshioka K, Kisukeda T, Zuinen R, Yasuda Y, Miyamoto K . Pharmacological effects of N-[2-[[2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]ethyl]hyaluronamide (diclofenac Etalhyaluronate, SI-613), a novel sodium hyaluronate derivative chemically linked with diclofenac. BMC Musculoskelet Disord. 2018; 19(1):157. PMC: 5964640. DOI: 10.1186/s12891-018-2077-8. View

13.

Smith M, Ghosh P . The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronate in the extracellular environment. Rheumatol Int. 1987; 7(3):113-22. DOI: 10.1007/BF00270463. View

14.

Dahl L, Dahl I, Engstrom-Laurent A, Granath K . Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies. Ann Rheum Dis. 1985; 44(12):817-22. PMC: 1001790. DOI: 10.1136/ard.44.12.817. View

15.

Balazs E, Bloom G, Swann D . Fine structure and glycosaminoglycan content of the surface layer of articular cartilage. Fed Proc. 1966; 25(6):1813-6. View

16.

Balazs E, WATSON D, DUFF I, Roseman S . Hyaluronic acid in synovial fluid. I. Molecular parameters of hyaluronic acid in normal and arthritis human fluids. Arthritis Rheum. 1967; 10(4):357-76. DOI: 10.1002/art.1780100407. View

17.

Asari A, Miyauchi S, Matsuzaka S, Ito T, Kominami E, Uchiyama Y . Molecular weight-dependent effects of hyaluronate on the arthritic synovium. Arch Histol Cytol. 1998; 61(2):125-35. DOI: 10.1679/aohc.61.125. View